Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923005 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17760540 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL4531927 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3673559 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL746205 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL25286686 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL5795993 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL418951 | 0.82 | ATM (0.59) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL16751022 | 0.82 | ATM (0.59) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17511112 | 0.80 | ATM (0.42) | ATMPIK3CDDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238300-A1 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4359082-A1 | HER2 MUTATION INHIBITORS | Array BioPharma Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230331730-A1 | CRYSTAL OF PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | disclosed |
| US-7985730-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | INCYTE CORPORATION | 2009-10-01 | — | — | US | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331730-A1 | CRYSTAL OF PYRIMIDINE COMPOUND | DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UMPS | ATM 1368/4885PIK3CD 2349/4885DPP4 399/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | ATM 2071/4885PIK3CD 3629/4885DPP4 2633/4885 |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | ATM 4495/4885PIK3CD 3793/4885DPP4 701/4885 |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | ATM 2546/4885PIK3CD 1805/4885DPP4 268/4885 |
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | ATM 1416/4885PIK3CD 706/4885DPP4 1636/4885 |
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | ATM 1958/4885PIK3CD 2062/4885DPP4 3146/4885 |
| US-20240238300-A1 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | EGFR, ERBB2, ERBB3 | ATM 139/4885PIK3CD 657/4885DPP4 1413/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | ATM 1711/4885PIK3CD 1880/4885DPP4 2584/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | ATM 1709/4885PIK3CD 46/4885DPP4 2706/4885 |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | CCR2, CXCR3, CCR5 | ATM 2379/4885PIK3CD 3597/4885DPP4 2716/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | ATM 444/4885PIK3CD 1035/4885DPP4 3709/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | ATM 2379/4885PIK3CD 3597/4885DPP4 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.